Endoloop Mediated Cardioplication to Treat Gastroesophageal Reflux Disease
NCT ID: NCT06153901
Last Updated: 2023-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
35 participants
INTERVENTIONAL
2023-12-10
2024-12-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
endoloop mediated cardioplication (ECLC)
The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
endoloop mediated cardioplication (ECLC) procedure
The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
endoloop mediated cardioplication (ECLC) procedure
The ECLC surgery first incises the mucosa and submucosa on the small curvature side and posterior side (approximately 3/4 of the total circumference) of the diaphragm level cardia until smooth muscle fibers are exposed; Fix the metal clip covered with nylon rope on the exposed smooth muscle layer, and finally tighten the nylon rope to achieve full folding of the cardia. After the surgery, the patient fasted overnight and received intravenous PPI treatment. On the second day after surgery, a fluid diet was restored and discharge was possible. ECLC is simple, easy to operate, relatively inexpensive, and minimally invasive, and is expected to become a new method for treating severe gastroesophageal reflux disease.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hiatal hernia ≤ 3cm
* Sliding hernia ≤ 3cm
* Classic reflux symptoms (heartburn, reflux) lasting for more than 6 months
* Daily PPIs ≥ 6 months
* Esophagitis (Los Angeles grade) Grade A, B, and C
* Gastroesophageal valve I-III grade (Hill grade)
* Pathological esophageal acid exposure (percentage of time with 24-hour esophageal PH\<4 \<4.2%)
* Normal or near normal esophageal movement (through manometry or impedance)
* The lower esophageal sphincter pressure (LESP) is between 5-15mmHg
* DeMeester score ≥ 14.7 or total reflux episodes\>73
* Patients who sign an informed consent form and voluntarily accept surgical expenses.
Exclusion Criteria
* ASA \>II
* Barrett's esophagus
* Hill IV level
* Large esophageal hiatal hernia\>3cm
* Esophagitis (Los Angeles grade) Grade D
* Peptic ulcer
* Primary esophageal motility disorders such as achalasia
* Previous esophageal or gastric surgery
* Uncontrolled systemic diseases
* Pregnancy or planned pregnancy within 1 year
* Have a history of cervical fusion surgery, esophageal diverticulum, scleroderma or dermatomyositis, eosinophilic esophagitis, liver cirrhosis or coagulation dysfunction, immune system diseases
* Patients deemed unsuitable for inclusion by researchers.
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shandong University
OTHER
Qilu Hospital of Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lu Jiaoyang
professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-QILU-LU 02
Identifier Type: -
Identifier Source: org_study_id